Novel therapy for children with chronic hormone deficiency provides lifeline for parents
- Alkindi® is the first replacement therapy specially designed for infants, children and adolescents with paediatric adrenal insufficiency
- Adrenal insufficiency is caused by a lack of the stress hormone cortisol – which can be fatal
- This new therapy, which has been developed by University of Sheffield spin-out company Diurnal, has been granted market authorisation by the European Medicine Agency.
Recent Blog Posts
A selection of articles from around the world in 2025
Here’s a selection of three articles from around the world in 2025 about CAH. They cover treatment methods and long term outcomes for people with CAH - making for interesting reading for anyone interested in or affected by CAH. These articles are not a recommendation...
COVID-19 Information & Guidance
As new guidance and information becomes available, we will do our best to link to it below - please check here for updates. If you contract COVID-19, remember to adhere to sick-day rules. Always seek guidance from your GP, endocrinologist or other appropriate medical...
Annual General Meeting – 2nd November, 3pm UK time in Oxford
The CAH Support Group is pleased to announce its 7th Annual General Meeting (AGM). It will be held in person at The Lighthouse, Oxford on Sunday 2nd November 2025 at 3pm UK time. A virtual Teams link is available on request. If you'd like to see the agenda and/or...